Allogene Halts Leukemia CAR-T Trial Amid Breyanzi Approval, Shifts Focus to Lymphoma and Autoimmune Research

Allogene Therapeutics has decided to cease enrollment in its Phase I trial of cemacabtagene ansegedleucel (cema-cel) for relapsed or refractory chronic lymphocytic leukemia (CLL), largely due to increased competition following the approval of Bristol Myers Squibb’s Breyanzi[1][2]. Breyanzi, which received approval earlier in the year for patients who have tried other treatments such as BTK and BCL2 inhibitors, has quickly become a dominant presence in the CLL market[2]. Analysts have noted that the slowing enrollment in Allogene's trial, combined with the emergence of alternative therapies, prompted the company to reconsider its focus away from competitive leukemia treatments[1]. Instead, Allogene will shift their efforts toward large B-cell lymphoma and explore research in autoimmune diseases[1][2].